Free Trial

LENSAR (LNSR) Scheduled to Post Earnings on Thursday

LENSAR logo with Medical background

LENSAR (NASDAQ:LNSR - Get Free Report) is set to issue its quarterly earnings data before the market opens on Thursday, November 7th. Parties that wish to register for the company's conference call can do so using this link.

LENSAR (NASDAQ:LNSR - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.53) earnings per share for the quarter. The company had revenue of $12.64 million during the quarter. LENSAR had a negative net margin of 27.83% and a negative return on equity of 30.69%.

LENSAR Stock Down 5.3 %

Shares of LNSR stock traded down $0.30 during trading on Friday, reaching $5.38. The company's stock had a trading volume of 22,725 shares, compared to its average volume of 32,377. The business has a fifty day moving average price of $4.84 and a 200-day moving average price of $4.47. The company has a market cap of $62.46 million, a price-to-earnings ratio of -3.45 and a beta of 0.64. LENSAR has a one year low of $1.80 and a one year high of $6.25.

LENSAR Company Profile

(Get Free Report)

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.

See Also

Earnings History for LENSAR (NASDAQ:LNSR)

Should you invest $1,000 in LENSAR right now?

Before you consider LENSAR, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENSAR wasn't on the list.

While LENSAR currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Why Whitestone REIT is Outperforming in 2024: 35% Growth & Monthly Dividends
Why SoundHound Stock Dip Could Mean Big Gains for 2025 Investors
Nintendo Stock: Buy Before the 2025 Switch Platform Hits!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines